CEACAM5 expression at intensity 2+/3+ in <50%, 50%–80%, and ≥80% of tumor cells was observed in 33.3%, 18.5%, and 48.1% of patients in cohort Q2W-LD and 25.0%, 25.0%, and 50.0% of patients in cohort Q3W, respectively. This evidence concerns the gene CEACAM5 and neoplasm.